5.53
02.34 (00.42%)
As of Mar 06, 2024
PUMA BIOTECHNOLOGY, INC. [PBYI]
As of Feb 29, 2024 | Source: Annual Report to the SEC
Company Overview
Puma Biotechnology, Inc. is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients.
| Country | United States |
| Headquarters | Los Angeles, California |
| Phone Number | (424) 248-6500 |
| Industry | Chemicals And Allied Products |
| Employees | 185 |
| CEO | Alan H. Auerbach |
| Website | www.pumabiotechnology.com |
Key fundamental financials profit of $5.80 million Revenue of $56.12 million Current Reporting Revenue Net Income Profit/Loss Sep 2023 $56.12 million $5.80 million profit Jun 2023 $54.57 million $2.13...
Key fundamental financials profit of $1.40 million Revenue of $52.78 million Current Reporting Revenue Net Income Profit/Loss Mar 2023 $52.78 million $1.40 million profit Sep 2022 $57,102 $360 loss Ju...
Key fundamental financials profit of $1.40 million Revenue of $52.78 million Puma Biotechnology, Inc. [PBYI] has reported $1.40 million profit for the fiscal quarter ending Mar 31, 2023. Revenue for t...
PUMA BIOTECHNOLOGY, INC. [PBYI] As of Aug 04, 2022| Source: Quarterly Report to the SEC We are a biopharmaceutical company with a focus on the development and commercialization of innovative products ...
PUMA BIOTECHNOLOGY, INC. [PBYI] As of May 10, 2017| Source: Quarterly Report to the SEC We are a biopharmaceutical company with a focus on the development and commercialization of innovative products ...
Financial Overview
| Revenue | 235,637 K |
| Operating Revenue | 32,640 K |
| Profits | 21,591 K |
| Net Cash | 7,884 K |
Management Effectiveness
| Return on Equity | 40.4% |
| Return on Assets | 9.37% |
| Turnover Ratio | 1.04 K |
| EBIT | 32,640 K |
Profit Ratios
| Gross Margin | 172,955 K |
| Operating Margin | 13.85% |
| Profit as % of Revenues | 801.05% |
| Profit as % of Assets | 9.54% |
| Profit as % of Stockholder Equity | 40.4% |
Balance Sheet and Cash Flow Measures
| Total Assets | 230,528 K |
| Total Liabilities | 177,086 K |
| Operating Cash Flow | 27,009 K |
| Investing Cash Flow | -19,125 K |
| Financing Cash Flow | 000 K |